Literature DB >> 30502486

Impact of bedside diagnosis of influenza in the paediatric emergency ward.

A Cantais1, O Mory2, A Plat2, A Bourmaud3, A Giraud2, M Costille2, B Pozzetto4, S Pillet4.   

Abstract

OBJECTIVES: This prospective study performed in the paediatric emergency department of the University Hospital of Saint-Etienne aimed to measure the impact of the 24/7 bedside use of the Veritor™ System (Becton Dickinson) on the reduction of supplementary investigations, hospital stay and antimicrobial use.
METHODS: Influenza virus A and B antigens were detected with a rapid influenza digital immunoassay (DIA) on nasopharyngeal aspirates (NPAs) sampled from the children consulting at the paediatric emergency department between January and March 2016 for influenza-like illness. The same NPA was tested by immunofluorescence and/or molecular routine assays. Before performing the DIA, the clinician filled in a questionnaire listing the tests that he/she would have prescribed in the absence of the rapid testing. The prescription of complementary investigations, antimicrobial treatments and hospital stay were also compared to those of the 3 previous years.
RESULTS: A total of 514 children with flu-like symptoms were included. The use of the DIA at bedside decreased the prescription of blood puncture by 47.9% (21.2% to 6.6%), of chest X-rays by 69.0% (33.3% to 10.3%), of lumbar puncture by 77.8% (7.0% to 1.6%), of urine culture by 79.2% (23.3% to 4.9%), of antibiotic treatments by 70.1% (16.9% to 5.1%), and of hospital stay by 25.0% (27.2% to 20.4%), resulting in a reduction of medical costs estimated to more than €69 000 in a season.
CONCLUSIONS: In addition to delivering a rapid aetiological diagnosis, this strategy saves medical costs and favours an antimicrobial stewardship strategy. However, further prospective studies are needed to confirm our findings.
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  24/7; BD Veritor; Cost-effectiveness impact; Digital reader; Immunoassay; Medical costs; Rapid influenza diagnostic test

Mesh:

Year:  2018        PMID: 30502486     DOI: 10.1016/j.cmi.2018.11.019

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  In-vitro diagnostic point-of-care tests in paediatric ambulatory care: A systematic review and meta-analysis.

Authors:  Oliver Van Hecke; Meriel Raymond; Joseph J Lee; Philip Turner; Clare R Goyder; Jan Y Verbakel; Ann Van den Bruel; Gail Hayward
Journal:  PLoS One       Date:  2020-07-06       Impact factor: 3.240

Review 2.  Multiplex Platforms for the Identification of Respiratory Pathogens: Are They Useful in Pediatric Clinical Practice?

Authors:  Susanna Esposito; Antonella Mencacci; Elio Cenci; Barbara Camilloni; Ettore Silvestri; Nicola Principi
Journal:  Front Cell Infect Microbiol       Date:  2019-06-04       Impact factor: 5.293

3.  Shortness of breath in children at the emergency department: Variability in management in Europe.

Authors:  Dorine Borensztajn; Joany M Zachariasse; Susanne Greber-Platzer; Claudio F Alves; Paulo Freitas; Frank J Smit; Johan van der Lei; Ewout W Steyerberg; Ian Maconochie; Henriëtte A Moll
Journal:  PLoS One       Date:  2021-05-05       Impact factor: 3.240

4.  The Etiology of Community-Acquired Pneumonia Correlates with Serum Inflammatory Markers in Children.

Authors:  August Wrotek; Julita Robakiewicz; Katarzyna Pawlik; Patryk Rudzinski; Izabela Pilarska; Aleksandra Jaroń; Aleksandra Imiełowska; Małgorzata Jarzębowska; Katarzyna Zabłocka; Teresa Jackowska
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

5.  Antibiotic utilization in hospitalized children under 2 years of age with influenza or respiratory syncytial virus infection - a comparative, retrospective analysis.

Authors:  Cihan Papan; Meike Willersinn; Christel Weiß; Michael Karremann; Horst Schroten; Tobias Tenenbaum
Journal:  BMC Infect Dis       Date:  2020-08-17       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.